A phase II trial of neoadjuvant cisplatin-fluorouracil followed by postoperative intraperitoneal floxuridine-leucovorin in patients with locally advanced gastric cancer

Annals of Oncology

Volumn 17, Issue 9, 2006, Pages 1404-1411

  Brenner, B ^a   Shah, M A ^a   Karpeh, M S ^a   Gonen, M ^a   Brennan, M F ^a   Coit, D G ^a   Klimstra, D S ^a   Tang, L H ^a   Kelsen, D P ^a  

^a Department of Obstetrics Gynecology   (United States)

Author keywords

Intraperitoneal treatment; Locally advanced gastric cancer; Neoadjuvant chemotherapy

Indexed keywords

CISPLATIN; FLOXURIDINE; FLUOROURACIL; FOLINIC ACID;

ADJUVANT CHEMOTHERAPY; ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD TOXICITY; CANCER LOCALIZATION; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DRUG EFFICACY; DRUG FATALITY; DRUG TOLERABILITY; FATIGUE; FEMALE; FOLLOW UP; GASTRECTOMY; HUMAN; LAPAROSCOPY; LEUKOPENIA; LIVER FAILURE; LYMPHADENECTOMY; MALE; MORBIDITY; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PERITONEAL DISEASE; PHASE 2 CLINICAL TRIAL; POSTOPERATIVE CARE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; QUALITY OF LIFE; STOMACH CANCER; STOMATITIS; SURGICAL MORTALITY; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

EID: 33748789900     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdl133     Document Type: Article

References (41)

1. Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture. Eur J Cancer 2001; 37 (Suppl 8): S4-66.
2. Jemal A, Murrey T, Samuels A et al. Cancer statistics, 2003. CA Cancer J Clin 2003; 53: 5-26.
3. Blot WJ, Devesa SS, Kneller RW, Fraumeni JF. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. J Am Med Assoc 1999; 265: 1287-1289.
4. Hermanek P, Maruyama K, Sobin LH. Stomach Cancer. In Hermanek P, Gospodarowicz MK, Henson D et al. (eds): Prognostic Factors in Cancer. Berlin: Springer 1995.
5. Hundahl S, Phillips J, Menck H. The National Cancer Data Base report on poor survival of U.S. gastric carcinoma patients treated with gastrectomy: Fifth edition American Joint Committee on Cancer staging, proximal disease, and the 'different disease' hypothesis. Cancer 2000; 88: 921-932.
6. MacDonald J, Smalley S, Benedetti J et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001; 345: 725-730.
7. Kelsen DP. Postoperative adjuvant chemoradiation therapy for patients with resected gastric cancer: Intergroup 116. J Clin Oncol 2000; 18: 32s-34s.
8. Smalley S, Gunderson L, Tepper J et al. Gastric surgical adjuvant radiotherapy consensus report: Rationale and treatment implementation. Int J Radiation Oncology Biol Phys 2002; 52: 283-293.
9. Shah MA, Kelsen DP. Post-operative adjuvant chemoradiotherapy in high risk gastric cancer. Der Chirurg 2002; 73: 325-330.
10. Cunningham D, Allum WH, Stenning SP, Weeden S. Perioperative chemotherapy in operable gastric and lower oesophageal cancer: Final results of a randomised, controlled trial (the MAGIC trial, ISRCTN 93793971). J Clin Oncol 2005; 23 (168, Part I of II): 308S.
11. Gunderson LL SH. Adenocarcinoma of the stomach: Areas of failure in a reoperation series (second or symptomatic look) clinicopathologic correlation and implications for adjuvant therapy. Int J Radiation Oncol Biol Phys 1992; 8: 1-11.
12. Dedrick R. Theoretical and experimental bases of intraperitoneal chemotherapy. Semin Oncol 1985; 12 (3 Suppl 4): 1-6.
13. Speyer JL, Sugarbaker PH, Collins JM et al. Portal levels and hepatic clearance of 5-fluorouracil after intraperitoneal administration in humans. Cancer-Res 1981; 41: 1916-1922.
14. Kelsen DP SL, Cohen AM, Yao TJ et al. Related articles. A phase I trial of immediate postoperative intraperitoneal floxuridine and leucovorin plus systemic 5-fluorouracil and levamisole after resection of high risk colon cancer. Cancer 1994; 74: 2224-2233.
15. Alberts DS, Markman M, Armstrong D et al. Intraperitoneal therapy for stage III ovarian cancer: A therapy whose time has come! J Clin Oncol 2002; 20: 3944-3946.
16. Kelsen DP. Adjuvant and neoadjuvant therapy for gastric cancer. Semin Oncol 1996; 23: 379-389.
17. Vanhoefer U, Rougier P, Wilke H et al. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol 2000; 18: 2648-2657.
18. Ensminger WD, Rosowsky A, Raso V et al. A clinical-pharmacological evaluation of hepatic arterial infusions of 5-fluoro-2′-deoxyuridine and 5-fluorouracil. Cancer Res 1978; 38 (11 part 1): 3784-3792.
19. Beahrs OH HD, Hutter RVP, Kennedy BJ (eds). Manual for Staging of Cancer. American Joint Committee on Cancer. Philadelphia: J.B. Lippincott 1992.
20. Fleming I, Cooper J, Henson D et al. American Joint Committee on Cancer Staging Manual. Philadelphia: Lippincott-Raven 1997.
21. Ruo L, Tickoo S, Klimstra DS et al. Long-term prognostic significance of extent of rectal cancer response to preoperative radiation and chemotherapy. Ann Surg 2002; 236: 75-81.
22. Rusch V, Klimstra D, Venkatraman E et al. Aberrant p53 expression predicts clinical resistance to cisplatin-based chemotherapy in locally advanced non-small cell lung cancer. Cancer Res 1995; 55: 5038-5042.
23. Kaplan EL, Meier P. Non-parametric estimation from incomplete observation. J Am Stat 1958; 53: 457-481.
24. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50: 163-170.
25. Lin LI. A concordance correlation coefficient to evaluate reproducibility. Biometrics 1989; 45: 255-268.
26. Allum W, Cunningham D, Weeden S et al. Perioperative chemotherapy and operable gastric and lower esophageal cancer: A randomized, controlled trial (the MAGIC trial ISRCNT93793971). Am Soc Clin Oncol 2003; 22: 249.
27. Estape J, Grau JJ, Lcobendas F et al. Mitomycin C as an adjuvant treatment to resected gastric cancer. A 10-year follow-up. Ann Surg 1991; 213: 219-221.
28. Laundry J, Tepper J, Wood W et al. Patterns of failure following curative resection of gastric carcinoma. Int J Radiation Oncol Biol Phys 1990; 19: 1357-1362.
29. Lowy AM, Mansfield PF, Leach SD et al. Response to neoadjuvant chemotherapy best predicts survival after curative resection of gastric cancer. Ann Surg 1999; 229: 303-308.
30. Crookes P, Leichman CG, Leichman L et al. Systemic chemotherapy for gastric carcinoma followed by postoperative intraperitoneal therapy: A final report. Cancer 1997; 79: 1767-1775.
31. Siewert JR, Bottcher K, Roder JD et al. Prognostic relevance of systemic lymph node dissection in gastric carcinoma. Br J Sung 1993; 80: 1015-1018.
32. Kelsen D, Karpeh M, Schwartz G, et al. Neoadjuvant therapy of high-risk gastric cancer: A phase II trial of preoperative FAMTX and postoperative intraperitoneal fluorouracil-cisplatin plus intravenous fluorouracil. J Clin Oncol 1996; 14: 1818.
33. Alexander HR, Grem JL, Hamilton JM et al. Thymidylate synthase protein expression association with response to neoadjuvant chemotherapy and resection for locally advanced gastric and gastroesophageal adenocarcinoma. Cancer J Sci Am 1995; 1: 49.
34. Kang YK, Choi DW, Im YH et al. A phase III randomized comparison of neoadjuvant chemotherapy followed by surgery versus surgery for locally advanced stomach cancer. Proc ASCO 1996; 15: 215.
35. Bonenkamp JJ, Songun J, Hermans J et al. Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients. Lancet 1995; 345: 745-748.
36. Cuschieri A, Weeden S, Fielding J et al. Patient survival after D1 and D2 resections for gastric cancer: Long-term results of the MRC randomized surgical trial. Surgical Cooperative group. Br J Cancer 1999; 79: 1522-1530.
37. Shah MA. Recent developments in the treatment of gastric carcinoma. Curr Oncol Rep 2002; 4: 213-221.
38. Janunger KG, Hafstrom L, Nygren P, Glimelius B. A systemic overview of chemotherapy effects in gastric cancer. Acta Onc 2001; 40: 309-326.
39. Bonadonna G, Valagussa P, Brambilla C et al. Primary chemotherapy in operable breast cancer: Eight-year experience at the Milan Cancer Institute. J Clin Oncol 1998; 16: 93-100.
40. Pisters KM, Kris MG, Gralla RJ et al. Pathologic complete response in advanced non-small-cell lung cancer following preoperative chemotherapy: implications for the design of future non-small-cell lung cancer combined modality trials. J Clin Oncol 1993; 11: 1757-1762.
41. Mandard AM, Dalibard F, Mandard JC et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma: clinicopathologic correlations. Cancer 1994; 73: 2680-2686.